Charles Schwab’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Charles Schwab’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-804	Closed	-$12K	–	3578
2022 Q3	$12K	Hold	804	–	–	﹤0.01%	3506
2022 Q2	$29K	Hold	804	–	–	﹤0.01%	3485
2022 Q1	$33K	Hold	804	–	–	﹤0.01%	3567
2021 Q4	$35K	Hold	804	–	–	﹤0.01%	3540
2021 Q3	$55K	Hold	804	–	–	﹤0.01%	3442
2021 Q2	$62K	Hold	804	–	–	﹤0.01%	3339
2021 Q1	$53K	Buy	804 +568	+241%	+$44.2K	﹤0.01%	3432
2020 Q4	$9K	Hold	236	–	–	﹤0.01%	3392
2020 Q3	$13K	Hold	236	–	–	﹤0.01%	3329
2020 Q2	$9K	Hold	236	–	–	﹤0.01%	3315
2020 Q1	$6K	Hold	236	–	–	﹤0.01%	3230
2019 Q4	$12K	Hold	236	–	–	﹤0.01%	3170
2019 Q3	$12K	Hold	236	–	–	﹤0.01%	3173
2019 Q2	$22K	Hold	236	–	–	﹤0.01%	3199
2019 Q1	$35K	Buy	+236	New	+$45.6K	﹤0.01%	3182

Other funds holding DMK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Charles Schwab's DMK Position: Q4 2022 in Review

Charles Schwab sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2022, closing a stake of 804 shares — an estimated $12K sold.

Charles Schwab first reported a position in DMK in Q1 2019 and held it in 15 quarters. The position peaked at $62K in Q2 2021. 48 funds tracked by Wall St. Rank hold DMK as of Q4 2022.

Charles Schwab reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2022 after selling out during the quarter.
Charles Schwab sold 804 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2022, an estimated $12K.
Charles Schwab first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2019 and held it in 15 quarters.
Charles Schwab's DMK Pharmaceuticals Corporation Common Stock position peaked at $62K in Q2 2021.
48 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2022.

Based on Charles Schwab's 13F filing for Q4 2022, filed 13 Feb 2023.